Compare OCGN & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCGN | EU |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.3M | 464.5M |
| IPO Year | N/A | N/A |
| Metric | OCGN | EU |
|---|---|---|
| Price | $1.60 | $3.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.00 | $4.00 |
| AVG Volume (30 Days) | ★ 6.2M | 3.1M |
| Earning Date | 03-04-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,370,000.00 | ★ $44,142,000.00 |
| Revenue This Year | $35.88 | $17.41 |
| Revenue Next Year | N/A | $95.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.26 | N/A |
| 52 Week Low | $0.52 | $1.01 |
| 52 Week High | $1.96 | $4.19 |
| Indicator | OCGN | EU |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 62.84 |
| Support Level | $1.57 | $3.06 |
| Resistance Level | $1.70 | $3.58 |
| Average True Range (ATR) | 0.14 | 0.22 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 22.45 | 57.22 |
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.